These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26825486)

  • 1. The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma.
    Pakravan M; Beni AN; Ghahari E; Varshochian R; Yazdani S; Esfandiari H; Ahmadieh H
    Am J Ther; 2017; 24(6):e676-e680. PubMed ID: 26825486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
    Williams RD; Novack GD; van Haarlem T; Kopczynski C;
    Am J Ophthalmol; 2011 Nov; 152(5):834-41.e1. PubMed ID: 21794845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
    Am J Ophthalmol; 2013 Oct; 156(4):731-6. PubMed ID: 23831221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
    Bacharach J; Dubiner HB; Levy B; Kopczynski CC; Novack GD;
    Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia.
    Hsu CR; Chen YH; Liu CP; Chen CH; Huang KK; Huang JW; Lin MN; Lin CL; Chen WR; Hsu YL; Lee TC; Chou SH; Tu CM; Hwang CS; Huang YC; Lu DW
    Invest Ophthalmol Vis Sci; 2019 Feb; 60(2):624-633. PubMed ID: 30735565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension.
    Kopczynski CC; Heah T
    Drugs Today (Barc); 2018 Aug; 54(8):467-478. PubMed ID: 30209441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study.
    Sit AJ; Gupta D; Kazemi A; McKee H; Challa P; Liu KC; Lopez J; Kopczynski C; Heah T
    Am J Ophthalmol; 2021 Jun; 226():262-269. PubMed ID: 33524367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the H-1152P, a potent Rho-associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes.
    Nishio M; Fukunaga T; Sugimoto M; Ikesugi K; Sumi K; Hidaka H; Uji Y
    Curr Eye Res; 2009 Apr; 34(4):282-6. PubMed ID: 19373576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy.
    Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
    J Glaucoma; 2017 Feb; 26(2):96-100. PubMed ID: 27661993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting.
    Park KH; Simonyi S; Kim CY; Sohn YH; Kook MS
    BMC Ophthalmol; 2014 Dec; 14():160. PubMed ID: 25519810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.
    Lewis RA; Levy B; Ramirez N; Kopczynski CC; Usner DW; Novack GD;
    Br J Ophthalmol; 2016 Mar; 100(3):339-44. PubMed ID: 26209587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Topically Administered Rho-Kinase Inhibitor AR-12286 in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma.
    Skaat A; Jasien JV; Ritch R
    J Glaucoma; 2016 Sep; 25(9):e807-14. PubMed ID: 27552517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma.
    Kusuhara S; Katsuyama A; Matsumiya W; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):809-814. PubMed ID: 29468405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers.
    Tanihara H; Inatani M; Honjo M; Tokushige H; Azuma J; Araie M
    Arch Ophthalmol; 2008 Mar; 126(3):309-15. PubMed ID: 18332309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia.
    Van de Velde S; Van Bergen T; Sijnave D; Hollanders K; Castermans K; Defert O; Leysen D; Vandewalle E; Moons L; Stalmans I
    Invest Ophthalmol Vis Sci; 2014 Feb; 55(2):1006-16. PubMed ID: 24474276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Long-Term Ripasudil 0.4% Instillation for the Reduction of Intraocular Pressure in Japanese Open-Angle Glaucoma Patients.
    Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Sotozono C; Kinoshita S
    J Ocul Pharmacol Ther; 2020 May; 36(4):229-233. PubMed ID: 32175792
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of travoprost 0.004% ophthalmic solution, six weeks after its laminated packaging had been removed, in primary open-angle glaucoma: a randomized, controlled, investigator-blinded study.
    Reis R; dos Santos LC; Vila MP; Magacho L
    Clin Ther; 2004 Dec; 26(12):2121-7. PubMed ID: 15823775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.
    Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2009-2015. PubMed ID: 28711991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.